Ironwood Pharmaceuticals Inc (IRWD) - Total Assets
Based on the latest financial reports, Ironwood Pharmaceuticals Inc (IRWD) holds total assets worth $396.06 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IRWD book value for net asset value and shareholders' equity analysis.
Ironwood Pharmaceuticals Inc - Total Assets Trend (2007–2024)
This chart illustrates how Ironwood Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Ironwood Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Ironwood Pharmaceuticals Inc's total assets of $396.06 Million consist of 52.0% current assets and 48.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.2% |
| Accounts Receivable | $81.89 Million | 23.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.86 Million | 0.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Ironwood Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IRWD market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ironwood Pharmaceuticals Inc's current assets represent 52.0% of total assets in 2024, a decrease from 87.7% in 2007.
- Cash Position: Cash and equivalents constituted 25.2% of total assets in 2024, down from 45.9% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 23.3% of total assets.
Ironwood Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Ironwood Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Ironwood Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.13 | 3.62 | 15.41 |
| Quick Ratio | 1.13 | 3.62 | 15.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $31.34 Million | $129.22 Million | $463.67 Million |
Ironwood Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Ironwood Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.59 |
| Latest Market Cap to Assets Ratio | 2.06 |
| Asset Growth Rate (YoY) | -25.5% |
| Total Assets | $350.91 Million |
| Market Capitalization | $722.29 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Ironwood Pharmaceuticals Inc's assets at a significant premium (2.06x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Ironwood Pharmaceuticals Inc's assets decreased by 25.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ironwood Pharmaceuticals Inc (2007–2024)
The table below shows the annual total assets of Ironwood Pharmaceuticals Inc from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $350.91 Million | -25.51% |
| 2023-12-31 | $471.07 Million | -57.20% |
| 2022-12-31 | $1.10 Billion | -2.34% |
| 2021-12-31 | $1.13 Billion | +101.51% |
| 2020-12-31 | $559.24 Million | +38.86% |
| 2019-12-31 | $402.75 Million | +21.29% |
| 2018-12-31 | $332.05 Million | -45.18% |
| 2017-12-31 | $605.67 Million | -14.67% |
| 2016-12-31 | $709.82 Million | +14.65% |
| 2015-12-31 | $619.12 Million | +85.64% |
| 2014-12-31 | $333.51 Million | +19.55% |
| 2013-12-31 | $278.96 Million | +21.34% |
| 2012-12-31 | $229.91 Million | +10.02% |
| 2011-12-31 | $208.98 Million | -30.66% |
| 2010-12-31 | $301.37 Million | +85.51% |
| 2009-12-31 | $162.45 Million | +15.44% |
| 2008-12-31 | $140.72 Million | +3.54% |
| 2007-12-31 | $135.91 Million | -- |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as wel… Read more